Efficacy and safety of bortezomib in patients with refractory and relapsed multiple myeloma (MM) outside clinical trials: Results from the catalan myeloma/amyloid study group (Gemmac)

被引：0
|
作者：
Cibeira, M. T.
Garcia, A.
Rosinol, L.
Petit, J.
Oriol, A.
Abella, E.
Soler, J. A.
Plensa, E.
Callis, M.
Gonzalez, Y.
Macia, J.
Orriols, J.
Escoda, L.
Tutusaus, M.
Heras, G.
Monzo, S.
Herranz, M. J.
Garcia, M.
Sureda, A.
Blade, J.
机构：
[1] Hosp Clin Barcelona, Barcelona, Spain
[2] H Germans Trias Pujol, Badalona, Spain
[3] H Mar Barcelona, Barcelona, Spain
[4] H Vall Hebron Barcelona, Barcelona, Spain
[5] H Josep Trueta Girona, Girona, Spain
[6] H Joan XXIII Tarragona, Althaia Xarxa Assistencial Manresa, Tarragona, Spain
[7] H Joan XXIII, Tarragona, Spain
[8] H Sagrat Cor Barcelona, Barcelona, Spain
[9] H Santa Tecla, Tarragona, Spain
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2007年 / 92卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：157 / 157
页数：1
相关论文
共 50 条
  • [31] An analysis of clinical trials assessing the efficacy and safety of single-agent thalidomide in patients with relapsed or refractory multiple myeloma
    Prince, H. Miles
    Schenkel, Brad
    Mileshkin, Linda
    LEUKEMIA & LYMPHOMA, 2007, 48 (01) : 46 - 55
  • [32] Safety and efficacy of vorinostat, bortezomib, doxorubicin and dexamethasone in a phase I/II study for relapsed or refractory multiple myeloma (VERUMM study: vorinostat in elderly, relapsed and unfit multiple myeloma)
    Waldschmidt, Johannes M.
    Keller, Alexander
    Ihorst, Gabriele
    Grishina, Olga
    Mueller, Stefan
    Wider, Dagmar
    Frey, Anna V.
    King, Kristina
    Simon, Roman
    May, Annette
    Tassone, Pierfrancesco
    Duyster, Justus
    Jung, Manfred
    Raje, Noopur
    Waesch, Ralph
    Engelhardt, Monika
    HAEMATOLOGICA, 2018, 103 (10) : E473 - E479
  • [33] Daily practice use of Bortezomib in relapsed/refractory multiple myeloma - Safety/efficacy results of a compassionate use program in Switzerland
    Freimann, Helene
    Calderoni, Antonello
    Cornu, Pierre
    Olie, Robert
    SWISS MEDICAL WEEKLY, 2007, 137 (21-22) : 317 - 322
  • [34] Network meta-analysis of randomized trials in multiple myeloma: efficacy and safety in relapsed/refractory patients
    Botta, Cirino
    Ciliberto, Domenico
    Rossi, Marco
    Staropoli, Nicoletta
    Cuce, Maria
    Galeano, Teresa
    Tagliaferri, Pierosandro
    Tassone, Pierfrancesco
    BLOOD ADVANCES, 2017, 1 (07) : 455 - 466
  • [35] Bortezomib, adriamycin and dexamethasone for patients with refractory and relapsed myeloma - results from the PAD (Ireland) study
    Morris, T. C. M.
    Kettle, P.
    Drake, M.
    Brunton, A.
    Cook, G.
    Leahy, M.
    O'Dwyer, M.
    Murray, M.
    Enright, H.
    McCloy, M.
    O'Gorman, P.
    Yong, K.
    O'Shea, T.
    Popat, R.
    Oakervee, H.
    Cavenagh, J.
    BRITISH JOURNAL OF HAEMATOLOGY, 2009, 145 : 16 - 16
  • [36] Bendamustine, Bortezomib and Dexamethasone (BVD) in Patients with Relapsed-Refractory Multiple Myeloma (MM): Updated Results of a Multicenter Phase II Study
    Offidani, Massimo
    Maracci, Laura
    Corvatta, Laura
    Marina, Liberati Anna
    Ballanti, Stelvio
    Attolico, Imma
    Caraffa, Patrizia
    Alesiani, Francesco
    di Toritto, Tommaso Caravita
    Gentili, Silvia
    Tosi, Patrizia
    Brunori, Marino
    Derudas, Daniele
    Ledda, Antonio
    Gozzetti, Alessandro
    Cellini, Claudia
    Malerba, Lara
    Mele, Anna
    Felici, Stefano
    Galimberti, Sara
    Mondello, Patrizia
    Pulini, Stefano
    Coppetelli, Ugo
    Fraticelli, Paolo
    Rizzi, Rita
    Leoni, Pietro
    BLOOD, 2014, 124 (21)
  • [37] THE EFFICACY OF BORTEZOMIB AND BORTEZOMIB-CONTAINING REGIMENS FOR TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA IN REAL CLINICAL PRACTICE
    Mitina, T.
    Golenkov, A.
    Kataeva, E.
    Lutskaya, T.
    Trifonova, E.
    Klinushkina, E.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 576 - 576
  • [38] Daratumumab combined with dexamethasone and lenalidomide or bortezomib in relapsed/refractory multiple myeloma (RRMM) patients: Report from the multiple myeloma GIMEMA Lazio group
    Fazio, Francesca
    Franceschini, Luca
    Tomarchio, Valeria
    Rago, Angela
    Garzia, Maria Grazia
    Cupelli, Luca
    Bongarzoni, Velia
    Andriani, Alessandro
    Gumenyuk, Svitlana
    Tafuri, Agostino
    Siniscalchi, Agostina
    Piciocchi, Alfonso
    De Fabritiis, Paolo
    De Rosa, Luca
    di Toritto, Tommaso Caravita
    Annibali, Ombretta
    Cantonetti, Maria
    Petrucci, Maria Teresa
    EJHAEM, 2022, 3 (01): : 121 - 128
  • [39] Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study
    Richardson, Paul G.
    Chanan-Khan, Asher A.
    Lonial, Sagar
    Krishnan, Amrita Y.
    Carroll, Michael P.
    Alsina, Melissa
    Albitar, Maher
    Berman, David
    Messina, Marianne
    Anderson, Kenneth C.
    BRITISH JOURNAL OF HAEMATOLOGY, 2011, 153 (06) : 729 - 740
  • [40] Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma
    Richardson, Paul G.
    Sonneveld, Pieter
    Schuster, Michael W.
    Irwin, David
    Stadtmauer, Edward A.
    Facon, Thierry
    Harousseau, Jean-Luc
    Ben-Yehuda, Dina
    Lonial, Sagar
    San Miguel, Jesus-F.
    Cavenagh, Jamie D.
    Anderson, Kenneth C.
    BRITISH JOURNAL OF HAEMATOLOGY, 2007, 137 (05) : 429 - 435
12345